Cullinan Therapeutics (CGEM) CEO pay: $2.3M actually paid in FY2025
$CGEM · Cullinan Therapeutics, Inc.Data through FY2025 — latest proxy filed 2026-04-28, checked for new filings 2026-08-21. Every number links to its source.
0.6× the tracked-company median CEO pay ($3.9M).
Pay vs. Performance (Compensation Actually Paid)
What the CEO was actually paid, by fiscal year
A negative figure is not pay returned. Compensation Actually Paid re-values unvested equity every year, so when a stock falls, the write-down on awards granted earlier can exceed everything granted that year. How CAP is calculated
What $100 invested was worth, company vs peer group
Pay-vs-Performance table
| FY | CEO pay on paper | CEO pay actually earned | Other top execs (avg) | Value of $100 invested since FY2023 | Same, peer group since FY2023 | Net income |
|---|---|---|---|---|---|---|
| 2025 | $5.1M | $2.3M | $1.6M | — | — | -$219.9M |
| 2024 | $7.7M | $5.8M | $2.0M | $115.45 | — | -$167.6M |
| 2023 | $4.0M | -$3.1M | $1.9M | $96.59 | — | -$155.1M |
Frequently asked
How much did the CGEM CEO make in 2025?
$2,330,168 in Compensation Actually Paid (CAP) as Cullinan Therapeutics, Inc.'s CEO (the filing reports this year's PEO pay without tagging which named executive it belongs to), updated 2026-04-28.
What is pay vs. performance (PvP)?
An SEC disclosure (Item 402(v), required since FY2022) linking named-executive pay to company total shareholder return (TSR) over up to 5 years.
What is Compensation Actually Paid (CAP)?
CAP starts from the Summary Compensation Table total and adjusts equity awards to fair value as of each year-end/vesting date, rather than grant-date value — see the glossary entry for the full walk-through.
Also on CGEM: SEC & DOJ enforcement actions · CEO track-record ranking · Glossary